Reem Abou Ghazaleh1, Matthieu Bruzzi2,3,4, Karen Bertrand1, Leila M'harzi1, Franck Zinzindohoue1,5, Richard Douard1,5,6, Anne Berger1,5, Sébastien Czernichow5,7, Claire Carette7, Jean-Marc Chevallier1,5,6. 1. Service de chirurgie digestive, Hôpital Européen Georges-Pompidou, 20 rue Leblanc, 75015, Paris Cedex, France. 2. Service de chirurgie digestive, Hôpital Européen Georges-Pompidou, 20 rue Leblanc, 75015, Paris Cedex, France. matthieu.bruzzi@aphp.fr. 3. Université Paris Descartes, Paris, France. matthieu.bruzzi@aphp.fr. 4. ANCRE, EA 4465, Université Paris Descartes, Paris, France. matthieu.bruzzi@aphp.fr. 5. Université Paris Descartes, Paris, France. 6. ANCRE, EA 4465, Université Paris Descartes, Paris, France. 7. Service de Nutrition, Hôpital Européen Georges-Pompidou, 20 rue Leblanc, 75015, Paris Cedex, France.
Abstract
PURPOSE OF REVIEW: Morbid obesity and type-2 diabetes mellitus (T2DM) are both major public health problems. Bariatric surgery is a proven and effective treatment for these conditions; laparoscopic Roux-en-Y gastric bypass (RYGB) is currently the gold-standard treatment. One-anastomosis gastric bypass (OAGB) is described as a simpler, safer, and non-inferior alternative to RYGB to treat morbid obesity. Concerning T2DM, experts of the OAGB procedure report promising metabolic results with good long-term remission of T2DM; however, heterogeneity within the literature prompted us to analyze this issue. RECENT FINDINGS: OAGB has gained popularity given its safety and long-term efficacy. Concerning the effect of OAGB for the treatment of T2DM, most reports involve non-controlled single-arm studies with heterogeneous methodologies and a few randomized controlled trials. However, this available literature supports the efficacy of OAGB for remission of T2DM in obese and non-obese patients. Two years after OAGB, the T2DM remission and improvement rate increased from 67 to 100%. The results were improved and stable in the long term. The 5-year T2DM remission rate increased from 82 to 84.4%. OAGB is non-inferior compared with RYGB and even superior to other accepted bariatric procedures, such as sleeve gastrectomy and adjustable gastric banding. OAGB is an efficient, safe, simple, and reversible procedure to treat T2DM. The literature reveals interesting results for T2DM remission in non-obese patients. High-level comparative studies are required to support these data.
PURPOSE OF REVIEW: Morbid obesity and type-2 diabetes mellitus (T2DM) are both major public health problems. Bariatric surgery is a proven and effective treatment for these conditions; laparoscopic Roux-en-Y gastric bypass (RYGB) is currently the gold-standard treatment. One-anastomosis gastric bypass (OAGB) is described as a simpler, safer, and non-inferior alternative to RYGB to treat morbid obesity. Concerning T2DM, experts of the OAGB procedure report promising metabolic results with good long-term remission of T2DM; however, heterogeneity within the literature prompted us to analyze this issue. RECENT FINDINGS:OAGB has gained popularity given its safety and long-term efficacy. Concerning the effect of OAGB for the treatment of T2DM, most reports involve non-controlled single-arm studies with heterogeneous methodologies and a few randomized controlled trials. However, this available literature supports the efficacy of OAGB for remission of T2DM in obese and non-obesepatients. Two years after OAGB, the T2DM remission and improvement rate increased from 67 to 100%. The results were improved and stable in the long term. The 5-year T2DM remission rate increased from 82 to 84.4%. OAGB is non-inferior compared with RYGB and even superior to other accepted bariatric procedures, such as sleeve gastrectomy and adjustable gastric banding. OAGB is an efficient, safe, simple, and reversible procedure to treat T2DM. The literature reveals interesting results for T2DM remission in non-obesepatients. High-level comparative studies are required to support these data.
Authors: M García-Caballero; M Valle; J M Martínez-Moreno; F Miralles; J A Toval; J M Mata; D Osorio; A Mínguez Journal: Nutr Hosp Date: 2012 Mar-Apr Impact factor: 1.057
Authors: Yingjun Quan; Ao Huang; Min Ye; Ming Xu; Biao Zhuang; Peng Zhang; Bo Yu; Zhijun Min Journal: Gastroenterol Res Pract Date: 2015-06-17 Impact factor: 2.260
Authors: Maurizio De Luca; Giacomo Piatto; Giovanni Merola; Jacques Himpens; Jean-Marc Chevallier; Miguel-A Carbajo; Kamal Mahawar; Alberto Sartori; Nicola Clemente; Miguel Herrera; Kelvin Higa; Wendy A Brown; Scott Shikora Journal: Obes Surg Date: 2021-05-03 Impact factor: 4.129
Authors: Matthieu Siebert; Lara Ribeiro-Parenti; Nicholas D Nguyen; Muriel Hourseau; Belinda Duchêne; Lydie Humbert; Nicolas Jonckheere; Grégory Nuel; Jean-Marc Chevallier; Henri Duboc; Dominique Rainteau; Simon Msika; Nathalie Kapel; Anne Couvelard; André Bado; Maude Le Gall Journal: Sci Rep Date: 2020-04-30 Impact factor: 4.379
Authors: Diego Paim Carvalho Garcia; Cyntia Ferreira Dos Reis; Luiza Ohasi de Figueiredo; Guilherme Vaz de Melo Mota; Leonardo Quinete Guimarães; Fernando Augusto de Vasconcellos Santos; Luiz Ronaldo Alberti; Thiago de Almeida Furtado Journal: Ann Med Surg (Lond) Date: 2019-11-17